|
Scott McCallister, M.D. has served as our Chief Medical Officer since October, 2006. Before joining Panacos, Dr. McCallister was Director of Virology, Global Medical Affairs at Bristol-Myers Squibb from 2005-2006, responsible for REYATAZ Phase IV global medical strategy along with review and approval of all HIV-related study protocols. Prior to this, Dr. McCallister was with Boehringer Ingelheim Pharmaceuticals (BI) from 2000-2005 as international medical leader for development of the HIV protease inhibitor APTIVUS. In this role at BI, he conducted nearly 30 Phase I-III clinical studies, served as lead medical author for the APTIVUS NDA and MAA (approved in US and EU, 2005), and was the primary spokesperson at the FDA Antiviral Drug Advisory Committee hearing. Prior to joining industry, Dr. McCallister was boarded in Infectious Diseases and Internal Medicine, served as an Assistant Clinical Professor at Rush Medical College and was Medical Director of the Howard Brown Health Center in Chicago (a low-cost clinic for indigent patients). He received his Bachelors degree from UCLA and his medical degree from St. George's University. | 